Indications › Neurodegenerative disease
GLP‑1 drugs in neurodegenerative disease
Which incretin agents are being studied in neurodegenerative disease, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 19
- Active
- 5
- Results scheduled
- 0
- Molecules studied
- 5
- Sponsors
- 14
No GLP‑1 or incretin drug is FDA-approved for neurodegenerative disease. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.
No GLP-1 or incretin drug is approved for neurodegenerative disease, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 6 of the 19 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 13 still in early phases. 14 distinct sponsors are involved, 5 of the trials run commercially and the rest by universities and hospitals.
Molecules studied in this indication
exenatide · liraglutide · lixisenatide · mazdutide · semaglutide
Trials on file
All 19 incretin trials recorded in this indication, active first.